In a study by Lin et al., priming with an HPV16 E6/E7 DNA vaccine and follow up with recombinant vaccinia/adenovirus or with a HPV16E6/E7-expressing tumor cell-based vaccine boost induced higher antigen-specific CD8+ T cell immune responses than vaccination with each vaccine individually35. Here, CD8A is linked to neoplasm.